Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.

Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved? Alternative pharmaceutical formulations of anti-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Caterina Cinti, Monia Taranta, Ilaria Naldi, Settimio Grimaldi
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/81c931ba19404e169be4fe92b6191047
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:81c931ba19404e169be4fe92b6191047
record_format	dspace
spelling	oai:doaj.org-article:81c931ba19404e169be4fe92b61910472021-11-18T06:58:23ZNewly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.1932-620310.1371/journal.pone.0017132https://doaj.org/article/81c931ba19404e169be4fe92b61910472011-02-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21373641/?tool=EBIhttps://doaj.org/toc/1932-6203Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved? Alternative pharmaceutical formulations of anti-cancer agents have been investigated in order to improve conventional chemotherapy treatment. These formulations are associated with problems like severe toxic side effects on healthy organs, drug resistance and limited access of the drug to the tumor sites suggested the need to focus on site-specific controlled drug delivery systems. In response to these concerns, we have developed a new drug delivery system based on magnetic erythrocytes engineered with a viral spike fusion protein. This new erythrocyte-based drug delivery system has the potential for magnetic-controlled site-specific localization and highly efficient fusion capability with the targeted cells. Here we show that the erythro-magneto-HA virosomes drug delivery system is able to attach and fuse with the target cells and to efficiently release therapeutic compounds inside the cells. The efficacy of the anti-cancer drug employed is increased and the dose required is 10 time less than that needed with conventional therapy.Caterina CintiMonia TarantaIlaria NaldiSettimio GrimaldiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 2, p e17132 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Caterina Cinti Monia Taranta Ilaria Naldi Settimio Grimaldi Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.
description	Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved? Alternative pharmaceutical formulations of anti-cancer agents have been investigated in order to improve conventional chemotherapy treatment. These formulations are associated with problems like severe toxic side effects on healthy organs, drug resistance and limited access of the drug to the tumor sites suggested the need to focus on site-specific controlled drug delivery systems. In response to these concerns, we have developed a new drug delivery system based on magnetic erythrocytes engineered with a viral spike fusion protein. This new erythrocyte-based drug delivery system has the potential for magnetic-controlled site-specific localization and highly efficient fusion capability with the targeted cells. Here we show that the erythro-magneto-HA virosomes drug delivery system is able to attach and fuse with the target cells and to efficiently release therapeutic compounds inside the cells. The efficacy of the anti-cancer drug employed is increased and the dose required is 10 time less than that needed with conventional therapy.
format	article
author	Caterina Cinti Monia Taranta Ilaria Naldi Settimio Grimaldi
author_facet	Caterina Cinti Monia Taranta Ilaria Naldi Settimio Grimaldi
author_sort	Caterina Cinti
title	Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.
title_short	Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.
title_full	Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.
title_fullStr	Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.
title_full_unstemmed	Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.
title_sort	newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/81c931ba19404e169be4fe92b6191047
work_keys_str_mv	AT caterinacinti newlyengineeredmagneticerythrocytesforsustainedandtargeteddeliveryofanticancertherapeuticcompounds AT moniataranta newlyengineeredmagneticerythrocytesforsustainedandtargeteddeliveryofanticancertherapeuticcompounds AT ilarianaldi newlyengineeredmagneticerythrocytesforsustainedandtargeteddeliveryofanticancertherapeuticcompounds AT settimiogrimaldi newlyengineeredmagneticerythrocytesforsustainedandtargeteddeliveryofanticancertherapeuticcompounds
_version_	1718424114989891584

Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.

Ejemplares similares